Role of Exenatide in Type 1 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00456300|
Recruitment Status : Completed
First Posted : April 4, 2007
Last Update Posted : December 1, 2010
|Condition or disease||Intervention/treatment||Phase|
|Type 1 Diabetes||Drug: Exenatide||Phase 4|
A large study in people with type 1 diabetes (T1DM) showed that lowering blood sugars stopped or delayed the occurrence of health problems. As a result of the study, treatment should try to control blood sugar as near to normal as safely possible.
In people without diabetes, the "after meal" blood sugar level is very carefully controlled. Insulin (the hormone that lowers blood sugar) and glucagon (hormone that raises blood sugar) play a key role in keeping this careful balance. We now know that a substance made by the body called GLP-1 also helps with this careful balance. GLP-1 works in four ways. First, it helps to stimulate the cells in the pancreas to produce more insulin. Secondly, it helps to "dampen" the glucagon response (glucagon is released after a meal and causes the blood sugar to rise). Thirdly, GLP-1 delays the digestion of food in the stomach. Lastly, it seems to "dampen" the appetite, which causes a person to eat less.
Exenatide is a medication that works very similar to GLP-1. Exenatide is FDA approved for use in adults.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||17 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Role of Exenatide in Type 1 Mellitus|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
- Area under the curve for glucose [ Time Frame: 5 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456300
|United States, Texas|
|Texas Children's Hospital/ Baylor College of Medicine|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Rubina Heptulla, MD||Baylor College of Medicine|